Merck & Co., Inc. (MRK)
Pre-market:
| Previous close | 128.26 |
| Open | 128.01 |
| Bid | 0.00 x 1000 |
| Ask | 128.03 x 900 |
| Day's range | 127.18 - 128.48 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,241,765 |
| Market cap | 322.987B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 140.12 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.42%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Simply Wall St.
Merck First Quarter 2024 Earnings: Beats Expectations
Merck ( NYSE:MRK ) First Quarter 2024 Results Key Financial Results Revenue: US$15.8b (up 8.9% from 1Q 2023). Net...
- Zacks
Here's Why Merck (MRK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Benzinga
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb
